Clinical patient characteristics
| Patient ID # | Clone | Age | Gender | CD4/CD8 Ratio | Absolute CD4 count | Treatments | Disease duration (y) |
|---|---|---|---|---|---|---|---|
| 395 | Vβ17 | 67 | M | 31 | 8,323 | I, TS, D, G, ECP | 3 |
| 326 | Vβ7.2 | 80 | M | 10.2 | 2,893 | I, ECP, B, A | 5 |
| 489 | Vβ13.2 | 46 | M | 17.8 | 1,991 | A, G | 1 |
| 414 | Vβ13.1 | 72 | M | 18 | 2,442 | ECP, TS, A, V, D, P, R, G | 0.5 |
| 478 | Vβ17 | 56 | F | 7.18 | 2,546 | TS, ECP | 1 |
| 484 | Vβ2 | 56 | F | 9.43 | 2,383 | TS, ECP, SS | 2 |
| 279 | Vβ13.1 | 72 | M | 13.5 | 2,504 | D, B, ECP, PUVA, I, A, V, G, | 5 |
| 475 | Vβ2 | 70 | F | 3.1 | 1,230 | UVB, ECP, A | 7 |
| 382 | Vβ1 | 75 | F | 2.67 | 1,029 | TS, UVB | 9 |
| 372 | Vβ17 | 64 | F | 94 | 11,083 | PUVA, ECP, UVB, TS, I | 2 |
| 365 | Vβ17 | 83 | M | 23 | 3,671 | B | 4 |
| 330 | Vβ13.1 | 72 | M | 18.6 | 5,028 | UVB, TS, B | 8 |
| 292 | Vβ17 | 67 | M | 32.3 | 5,356 | PUVA, UVB, TS, I, ECP, B, G | 13 |
| 119 | Vβ13.1 | 78 | F | 14.5 | 2,800 | PUVA, D, I, ECP, V, B | 6 |
| 99 | Vβ17 | 81 | F | 12.56 | 3,530 | PUVA, UVB, TS | 7 |
| 44 | Vβ14 | 96 | F | 6.52 | 1,495 | I, SS | 16 |
| 472 | Vβ2 | 88 | M | 93 | 3,798 | ECP, B, PUVA, A | 3 |
Abbreviations: I, IFN-α2a; ECP, extracorporeal photochemotherapy; V, vorinostat; B, bexarotene, D, denileukin diftitox; TS, topical steroids; SS, systemic steroids; G, gemcitabine; A, alemtuzumab; P, pralatraxate; R, romidepsin; PUVA, psoralen + UVA treatment.